Life Sciences Regulation To Watch In 2013

Law360, New York (January 1, 2013, 5:14 PM EST) -- A wave of new regulation is headed for the life sciences sector in 2013, promising to radically reform how the industry handles drug approvals, plant inspections, promotional activities and interactions with doctors, among other practices.

"2013 could be a big year for regulation," said Areta L. Kupchyk, a Nixon Peabody partner who counsels clients on FDA interactions.

Here’s a look at key regulations experts will keep an eye on in 2013.

The Biosimilars Waiting Game 

A lengthy wait for detailed guidance on biosimilars might finally end in...
To view the full article, register now.